CYNA
Cynapsus TherapeuticsNASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Wed, Aug. 31, 5:56 PM
    • Cynapsus Therapeutics (NASDAQ:CYNA) +117.9% AH after agreeing to be acquired by privately-held Sunovion Pharmaceuticals for $40.50/share in cash, or ~$624M.
    • Sunovion would acquire CYNA's APL-130277 product candidate, which is designed to be an easy-to-use, on-demand treatment option for Parkinson’s disease.
    • Sunovion says the deal expands its leadership in treatments for central nervous system disorders.
    | Wed, Aug. 31, 5:56 PM | 17 Comments